In the field of growth investing, merging a strict technical system with an emphasis on fundamental momentum can be a strong method for spotting possible leaders. One technique that shows this is the approach made known by trader Mark Minervini, which depends on his Specific Entry Point Analysis (SEPA). This process aims to locate stocks showing firm price movements, backed by quickening fundamental growth, just as they are ready for their next major move forward. The aim is not to forecast what comes next, but to methodically find companies where the technical and fundamental views match, indicating a greater chance of ongoing strong performance.
A vital part of this approach is the Minervini Trend Template, a group of fixed technical screens made to confirm a stock is in a verified, firm upward movement. The template requires that a stock’s price and important moving averages are arranged in a positive way, that it is trading well above its 52-week low and close to its peaks, and that it shows better relative performance compared to the wider market.
Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA) now offers a strong example for this merged method, as it seems to meet both the strict technical rules of the Trend Template and the fast growth numbers desired by momentum investors.
Fitting the Minervini Trend Template
An examination of KNSA’s technical position shows it meets the vital points of the Trend Template, which is made to screen for stocks in a controlling Stage 2 upward move.
- Price vs. Moving Averages: The stock is trading well above its rising 50-day ($45.34), 150-day ($41.30), and 200-day ($38.50) simple moving averages. This arrangement confirms a continued upward movement across several time periods.
- Moving Average Arrangement: The 50-day SMA is above both the 150-day and 200-day SMAs, and the 150-day is above the 200-day. This ordered positive arrangement points to quickening momentum and is a sign of leading stocks.
- Nearness to Highs: With a present price near $48.82, KNSA is trading within 1% of its 52-week high of $49.33. The template stresses that real market leaders reach new highs; this nearness is a signal of firmness, not a caution.
- Separation from Lows: The stock’s price is about 167% above its 52-week low of $18.26, showing a firm recovery and trend change has already happened.
- Better Relative Strength: Maybe most significantly, KNSA has a ChartMill Relative Strength (CRS) score of 93.86, meaning it has done better than almost 94% of all stocks over the last year. This outstanding relative strength is a central idea of the Minervini method, spotting stocks that are leaders, not followers.
This technical base is important because it clearly shows that institutional money is entering the stock, creating a favorable current of demand. Trading against a firm, confirmed trend is statistically unfavorable; the Trend Template makes an investor concentrate on the direction of greatest momentum.
The Fast-Growth Fundamental Driver
A firm chart is frequently a sign of a getting better business. The "High Growth Momentum" part of the screen looks into the fundamental quickening that usually powers such firm price movements. KNSA’s latest financial results show the kind of fast growth that draws institutional notice and can support a major price move forward.
- Earnings Growth Quickening: The company has reported very high year-over-year earnings per share (EPS) growth in recent quarters, including 241.7% in the latest quarter. This is not a single event; the earlier quarters showed growth of 227.8% and 483.3%. This sequence of quickening, triple-digit EPS growth is just what growth investors look for.
- Strong Revenue Growth: Top-line growth is also very high, with recent quarterly sales rising by 65.0% and 61.2%. Firm revenue growth confirms that earnings gains are powered by business growth, not only cost reduction.
- Positive Earnings Surprises: KNSA has surpassed analyst EPS predictions in two of the last four quarters, with an average beat of almost 24%. Regularly beating expectations builds trust with the investment community and can lead to higher predictions for future estimates.
- Moving to Profitability: After times of investment and development, the company is now making positive and growing profits. Its trailing twelve-month EPS is $0.74, and it has reported positive profit margins in recent quarters. This change to profitability is a key turning point for biopharma companies and a major reason for stock revaluation.
Minervini’s view stresses that "big earnings draw big notice." KNSA’s fundamental picture, marked by quick, speeding growth in both profits and sales, gives the clear reason that explains the firmness seen on the chart. It is the story behind the momentum.
Technical Condition and Setup Overview
ChartMill’s own analysis gives a combined view of KNSA’s technical condition. The stock receives a perfect Technical Rating of 10/10, showing outstanding trend firmness, momentum, and relative performance. Both its long-term and short-term trends are scored as positive, and it is clearly doing better than most stocks within the competitive biotechnology field.
The analysis also mentions a Setup Rating of 6/10. This shows that while the stock is technically very good, it is now trading in the middle of its recent range ($44.36 - $49.33) instead of in a tight, wound-up pattern best for a new breakout entry. The report finds clear support areas below the present price, which can help outline risk, and points out immediate resistance near the $48.83 level. A full list of the support, resistance, and a sample trade plan can be seen in the complete ChartMill Technical Report for KNSA.
Locating Comparable Chances
The merging of a Minervini-style trend template and high-growth fundamental screens is a methodical way to search for possible leadership candidates. KNSA was found using such a process. Investors curious about finding other stocks that now meet this mix of technical and fundamental rules can review the preset screen: High Growth Momentum + Trend Template.
To conclude, Kiniksa Pharmaceuticals (KNSA) shows a profile that matches a disciplined growth and momentum strategy. It displays the standard technical marks of a market leader in a firm upward movement, supported by fundamental results showing quick speeding in profitability and sales. While the present trading pattern may ask for waiting for a best entry point, the coming together of these points makes it a stock worth close watching by investors focused on high-growth chances within confirmed upward movements.
Disclaimer: This article is for informational and educational purposes only. It is not a recommendation to buy or sell any security. The analysis is based on data and methods thought to be dependable, but no promise is made about its correctness or fullness. Investing includes risk, including the possible loss of principal. Always do your own research and think about your financial position and risk tolerance before making any investment choices. Please read our full disclaimer here.